Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status

Authors

• M S. Brose

Publication/Presentation Date

11-2023

Volume

34

Issue

4

First Page

1708

Last Page

1709

Published In/Presented At

https://doi.org/10.1016/j.annonc.2023.10.319

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article